August 4, 2020
Balt to Commercialize Cerus Endovascular's Contour and Neqstent Devices in Germany
August 4, 2020—Cerus Endovascular Ltd. and AB Medica Deutschland Verwaltungs GmbH, a wholly owned subsidiary of Balt, announced a strategic distribution agreement providing AB Medica with the exclusive rights to market and sell Cerus Endovascular's Contour neurovascular system and the Neqstent coil-assisted flow diverter device in Germany.
Cerus Endovascular is a privately held, commercial-stage medical device company headquartered in Fremont, California. AB Medica is based in Düsseldorf, Germany. The terms of the agreement were not disclosed.
Thomas Liebig, MD, who is Professor at the Institute for Diagnostic and Interventional Neuroradiology at Ludwig-Maximillians Universität München (LMU) in Munich, Germany, serves as Principal Investigator of the CERUS clinical trial of the Contour neurovascular system.
Professor Liebig commented in the announcement, “I am delighted with the progress that Cerus has made thus far in Germany. At LMU, we performed the first case with the system in Germany back in 2018 and have been using the device consistently since CE Mark was granted.”
Cerus Endovascular's President, Stephen Griffin, PhD, stated, “Our partnership with Balt, an internationally recognized pioneer in the neurovascular sector, reflects the strength of our innovative product line and will provide significantly increased awareness and more rapid penetration of both the Contour neurovascular system and the Neqstent device within Germany, the largest market within the European Union (EU).
“Physicians in Germany have indicated their desire for greater access to our products and have, therefore, been very supportive of our decision to partner locally with AB Medica. We are excited to begin working closely together and eventually, to extending the distribution agreement into other key EU countries.”